<DOC>
	<DOCNO>NCT00100087</DOCNO>
	<brief_summary>The study investigate safety feasibility use TheraSight ( TM ) Brachytherapy System treatment wet age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Safety Study Treatment Wet Macular Degeneration Using TheraSight ( TM ) Ocular Brachytherapy System</brief_title>
	<detailed_description>This multi-center randomized study three dos radiation ( assigned 1:1:1 ) deliver TheraSight ( TM ) Brachytherapy System participant choroidal neovascularization ( CNV ) secondary wet ( exudative ) AMD . Each participant receive single dose radiation deliver one-time brachytherapy . Participants follow three year radiation treatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Age 50 year old . Active primary recurrent subfoveal CNV secondary AMD minimally classic occult lesion , active lesion define one following : ) An increase &gt; 10 % lesion size ( great linear dimension ) screen fluorescein angiography compare previous fluorescein angiography 180 day precede screen visit b ) Subretinal hemorrhage associate CNV within 90 day screen visit . c ) Visual acuity loss &gt; 1 Snellen line screen visual acuity compare previous visual acuity 180 day precede screen Lesion &lt; 6 mm great linear dimension ( GLD ) Submacular blood must comprise less 75 % total lesion Subretinal fibrosis must comprise less 25 % total lesion Study eye bestcorrected vision 20/100 poorer measure ETDRS chart ( &lt; 48 letter correct ) Fellow eye bestcorrected vision least one line well ETDRS chart bestcorrected vision study eye HbA1c &lt; 6 % Read sign informed consent Prior AMD therapy treatment , include limit laser photodynamic therapy . Current plan participation next 180 day experimental trial involve treatment neovascular AMD study eye , ocular device , trial involve treatment ocular condition AMD . Prior ophthalmic surgery study eye cataract extraction and/or capsulotomy . A minimum interval 180 day must elapse cataract extraction capsulotomy study enrollment . Likely need cataract surgery study eye 180 day follow TheraSight ( TM ) System treatment . Presence eye disease could compromise visual acuity study eye , clinical judgment evaluate study ophthalmologist , might create special risk study participant . CNV due cause ocular histoplasmosis pathologic myopia . Endstage fibrotic disciform lesion . Diabetes require diet modification , medication , insulin . Current history malignancy ( except participant basal cell carcinoma treat successfully , malignancy operate treated remission five year prior inclusion trial ) . Hypertensive retinopathy . Major cardiovascular cerebrovascular event within last year ; example include congestive heart failure , myocardial infarction , stroke . Inability complete followup . Allergy fluorescein dye . Previous radiation study eye . Pregnancy time surgical procedure .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>macular degeneration</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>retinal degeneration</keyword>
	<keyword>retinal disease</keyword>
</DOC>